Amendment

(Amendment under the provision of Article 34 of the Treaty)

CLAIMS:

1. (Deleted)

2. (Deleted)

3. (After amendment)

A method for detecting cognitive dysfunction diseases comprising measuring a biomarker of (a) or (b) and a biomarker of (c):

(a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;

(b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and

(c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.

4. (After amendment)

The method for detecting cognitive dysfunction diseases according to Claim 3 comprising measuring two biomarkers, namely, a biomarker of the

(a) and a biomarker of the (c) when the detection of the cognitive dysfunction diseases is the detection of mild cognitive impairment or measuring two biomarkers, namely, a biomarker of the (b) and a biomarker of the (c) biomarker when the detection of the cognitive dysfunction diseases is Alzheimer's disease.

5. (After amendment)

A cognitive dysfunction disease detection kit for measuring a biomarker of the following (a) or (b) and a biomarker of the following (c) for detecting cognitive dysfunction diseases:

(a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;

(b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and,

(c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof;

6. The cognitive dysfunction disease detection kit according to Claim 5 comprising an antibody against the biomarker or aptamer.

7. A method for selecting a combination of multiple biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers comprising:

measuring two or more biomarkers for cognitive dysfunction diseases in a biological sample from a subject;

conducting an analysis of the measurement results of each of the two or more biomarkers by a logistic regression analysis; and

selecting a combination of the biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers based on the results of the analysis.

CLAIMS:

1. A method for detecting cognitive dysfunction diseases comprising measuring a biomarker of (a) or (b) and a biomarker of (c):

(a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;

(b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and

(c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.

2. The method for detecting cognitive dysfunction diseases according to Claim 1 comprising measuring two biomarkers, namely, a biomarker of the (a) and a biomarker of the (c) when the detection of the cognitive dysfunction diseases is the detection of mild cognitive impairment or measuring two biomarkers, namely, a biomarker of the (b) and a biomarker of the (c) biomarker when the detection of the cognitive dysfunction diseases is Alzheimer's disease.

3. A cognitive dysfunction disease detection kit for measuring a biomarker of the following (a) or (b) and a biomarker of the following (c) for detecting cognitive dysfunction diseases:

(a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;

(b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and,

(c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof;

4. The cognitive dysfunction disease detection kit according to Claim 3 comprising an antibody against the biomarker or aptamer.

5. A method for selecting a combination of multiple biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers comprising:

measuring two or more biomarkers for cognitive dysfunction diseases in a biological sample from a subject;

conducting an analysis of the measurement results of each of the two or more biomarkers by a logistic regression analysis; and

selecting a combination of the biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers based on the results of the analysis.